RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251

Benzinga · 3d ago
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $203 to $251.